Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Tufts Medical Center
Study ID
NCT03159936
Phase
EARLY_PHASE1
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Evaluate the activity and safety of oral tofacitinib in adult patients with discoid lupus erythematosus with or without concurrent SLE.

Key Dates

Start date
Apr 3, 2017
Status verified
Jan 2022
Primary completion
May 13, 2020
Completion
Jun 10, 2020

Study Design

Enrollment
5 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Tofacitinib citrate
    All participants will take one 5 mg tablet by mouth in the morning and one tablet by mouth in the evening for the 6-month study duration.

Primary Outcome Measure

Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) [ Time Frame: week 24 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Tufts Medical CenterBostonMassachusetts02111-

Find similar trials in Boston, MA

By condition
Lupus (SLE)
By specialty
RheumatologyAutoimmune disease
By research site
Tufts Medical Center· Boston, MA

Related Studies